Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Leap Therapeutics stock | 1.56

Own Leap Therapeutics stock in just a few minutes.

Posted

Fact checked

Leap Therapeutics, Inc is a biotechnology business based in the US. Leap Therapeutics shares (LPTX) are listed on the NASDAQ and all prices are listed in US Dollars. Leap Therapeutics employs 24 staff and has a trailing 12-month revenue of around USD$1.1 million.

How to buy shares in Leap Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Leap Therapeutics. Find the stock by name or ticker symbol: LPTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Leap Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.56, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Leap Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Leap Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Leap Therapeutics share price

Use our graph to track the performance of LPTX stocks over time.

Leap Therapeutics shares at a glance

Information last updated 2020-11-27.
Latest market close USD$1.56
52-week range USD$0.6851 - USD$3.18
50-day moving average USD$1.8713
200-day moving average USD$2.0177
Wall St. target price USD$5.1
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.663

Buy Leap Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Leap Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Leap Therapeutics price performance over time

Historical closes compared with the close of $1.56 from 2020-11-16

1 week (2020-11-23) 4.70%
1 month (2020-10-30) -20.00%
3 months (2020-08-28) -10.34%
6 months (2020-05-29) -34.18%
1 year (2019-11-29) 116.67%
2 years (2018-11-30) -57.84%
3 years (2017-11-30) -75.85%
5 years (2015-11-27) N/A

Is Leap Therapeutics under- or over-valued?

Valuing Leap Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Leap Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Leap Therapeutics's PEG ratio

Leap Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Leap Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Leap Therapeutics financials

Revenue TTM USD$1.1 million
Gross profit TTM USD$0
Return on assets TTM -49.06%
Return on equity TTM -98.13%
Profit margin 0%
Book value $0.891
Market capitalisation USD$94.9 million

TTM: trailing 12 months

Shorting Leap Therapeutics shares

There are currently 562,166 Leap Therapeutics shares held short by investors – that's known as Leap Therapeutics's "short interest". This figure is 4.5% up from 537,722 last month.

There are a few different ways that this level of interest in shorting Leap Therapeutics shares can be evaluated.

Leap Therapeutics's "short interest ratio" (SIR)

Leap Therapeutics's "short interest ratio" (SIR) is the quantity of Leap Therapeutics shares currently shorted divided by the average quantity of Leap Therapeutics shares traded daily (recently around 759683.78378378). Leap Therapeutics's SIR currently stands at 0.74. In other words for every 100,000 Leap Therapeutics shares traded daily on the market, roughly 740 shares are currently held short.

However Leap Therapeutics's short interest can also be evaluated against the total number of Leap Therapeutics shares, or, against the total number of tradable Leap Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Leap Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Leap Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0141% of the tradable shares (for every 100,000 tradable Leap Therapeutics shares, roughly 14 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Leap Therapeutics.

Find out more about how you can short Leap Therapeutics stock.

Leap Therapeutics share dividends

We're not expecting Leap Therapeutics to pay a dividend over the next 12 months.

Leap Therapeutics share price volatility

Over the last 12 months, Leap Therapeutics's shares have ranged in value from as little as $0.6851 up to $3.18. A popular way to gauge a stock's volatility is its "beta".

LPTX.US volatility(beta: 1.58)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Leap Therapeutics's is 1.5821. This would suggest that Leap Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Leap Therapeutics overview

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. Its clinical stage programs also include TRX518, a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site